The patient-derived tumor xenograft (PDX) model derived from the patient's primary tumor tissue differs from the traditional cell-derived xenograft (CDX) model and genetically engineered mouse model, which is directly established by using the patient's tumor tissue. The subcutaneous xenograft tumor model can better retain the special functional gene structure and biological markers of the tumor in the individual, which is closer to the individual clinical biological characteristics and can reproduce the complex state of human cancer, such as the heterogeneity of tumor cells. It is an internationally recognized mouse xenograft tumor model that best represents the genetic information characteristics of human tumors and can provide better predictions for drug screening and efficacy observation. In recent years, PDX technology has developed rapidly, showing its essential role in drug screening, curative effect evaluation, prediction of clinical treatment effects during the same pe...
Integrated Drug Discovery Services- Chemistry, Biology & Preclinical Services